The Massachusetts-based biotechnology company, Moderna, Inc. has announced that a vaccine it is producing against COVID-19 was found to be 94.5 percent effective at preventing the virus in a Phase 3 trial.
The so-called COVE study of the mRNA-1273 vaccine has involved more than 30,000 participants in the US.
The results announced on November 16 were based off an analysis of 95 cases of COVID-19 observed in participants. The study found that 90 of those who tested positive had been given a placebo while the five who were infected had been given the mRNA-1273 vaccine.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate," Moderna CEO Stéphane Bancel said in a statement.
“All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” he said.
This footage, provided by Moderna, shows production at the company’s Manufacturing Technology Center in Massachusetts. Credit: Moderna, Inc. via Storyful